Mangalam Drugs & Organics Limited

MANGALAM

INE584F01014

Pharmaceuticals

Market Closed - Bombay S.E. Other stock markets 06:00:53 2024-06-10 am EDT			5-day change	1st Jan Change
105 ^INR	-0.33%		+3.34%	+6.99%

Feb. 13	Mangalam Drugs & Organics Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	CI
2023	Mangalam Drugs & Organics Limited Reports Earnings Results for the Half Year Ended September 30, 2023	CI

Mangalam Drugs & Organics Limited Approves Appointment of Nidhi Mundada as Additional Director (Non-Executive & Independent)

May 28, 2018 at 05:15 am EDT

Mangalam Drugs & Organics Limited at its board meeting held on 28 May 2018, approved appointment of Mrs. Nidhi Mundada as Additional Director (Non-Executive & Independent) of the company, effective 28 May, 2018.

Latest news about Mangalam Drugs & Organics Limited

Mangalam Drugs & Organics Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	Feb. 13	CI
Mangalam Drugs & Organics Limited Reports Earnings Results for the Half Year Ended September 30, 2023	Nov. 08	CI
Mangalam Drugs & Organics Limited Reports Earnings Results for the First Quarter Ended June 30, 2023	23-08-10	CI
Mangalam Drugs & Organics Limited Reports Earnings Results for the Full Year Ended March 31, 2023	23-05-30	CI
Mangalam Drugs & Organics Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2023	23-05-30	CI
Mangalam Drugs & Organics Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022	23-02-13	CI
Mangalam Drugs & Organics Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022	22-11-11	CI
Mangalam Drugs & Organics Limited Reports Earnings Results for the First Quarter Ended June 30, 2022	22-08-05	CI
Mangalam Drugs & Organics Limited Reports Earnings Results for the Full Year Ended March 31, 2022	22-05-27	CI
Mangalam Drugs & Organics Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2022	22-05-26	CI
Mangalam Drugs & Organics Limited Announces Appointment of Shri Rakesh K. Milwani as an Additional Director (Non- Executive Non- Independent Director)	22-03-10	CI
Mangalam Drugs & Organics Limited Announces Executive Changes	22-02-04	CI
Mangalam Drugs & Organics Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2021	22-02-04	CI
Mangalam Drugs & Organics Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2021	21-11-12	CI
Mangalam Drugs & Organics Limited Announces Earnings Results for the First Quarter Ended June 30, 2021	21-08-12	CI
Mangalam Drugs & Organics : and Organics Commissions New Manufacturing Facility in Gujarat, India	21-06-20	MT
Mangalam Drugs & Organics Limited Provides Update on Setting-Up of New Intermediate Manufacturing Facility At Unit 1 Located in Vapi, Gujarat	21-06-18	CI
Mangalam Drugs & Organics' : Net Profit Plummets in Fiscal Q4; Shares Plunge 8%	21-05-21	MT
Mangalam Drugs & Organics Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2021	21-05-20	CI
Mangalam Drugs & Organics Limited Reports Earnings Results for the Third Quarter Ended December 31, 2020	21-02-11	CI
Mangalam Drugs & Organics Limited Announces Resignation of Prashant J. Pandit as Independent Director	20-12-22	CI
Mangalam Drugs & Organics Limited Announces Resignation of Prashant J. Pandit, Independent Director	20-12-07	CI
Mangalam Drugs & Organics Limited Announces Change in Directorate	20-11-21	CI
Mangalam Drugs & Organics Limited Reports Earnings Results for the Second Quarter Ended September 30, 2020	20-11-12	CI
Mangalam Drugs & Organics Limited Reports Earnings Results for the First Quarter Ended June 30, 2020	20-08-10	CI

Chart Mangalam Drugs & Organics Limited

Duration

Period

More charts

Company Profile

Mangalam Drugs and Organics Limited is an India-based manufacturer of active pharmaceutical ingredients (APIs) and intermediates. Under the Company's Fight Malaria Program, it supplies anti-malaria APIs worldwide. Its products include API, intermediates and specialty chemicals. Its API products include acyclovir, amodiaquine, artemether, artesunate, atazanavir sulfate, bisoprolol fumarate, chloroquine phosphate, furosemide and dolutegravir sodium. The Company's intermediates products include 4,6-Dichloro-5-Methoxy Pyrimidine; 4,7- dichloroquinoline; ortho phenoxy methane sulfonanilide; tenofovir alafenamide base, and tenofovir disoproxil base. Its specialty chemicals products include L (+)-menthol; 2,3-dihydrophthalazine-1,4-dione or phthalazine-1,4-dione, and 4-cynoethyl-2-methyl phenol. Its pipeline APIs (under development) include Ganaplacide (IH), Tafenoquine Succinate (IH) and Pretomanid (IH). Its pipeline APIs (developed at research and development) is Bictegravir Na (IH).

Sector

Pharmaceuticals

Calendar

2024-08-07 - Q1 2025 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Generic Pharmaceuticals

	1st Jan change	Capi.
MANGALAM DRUGS & ORGANICS LIMITED	+6.99%	19.98M
SUN PHARMACEUTICAL INDUSTRIES LTD.	+20.14%	43.3B
OTSUKA HOLDINGS CO., LTD.	+23.67%	22.22B
SANDOZ GROUP AG	+16.89%	15.43B
CIPLA LIMITED	+23.10%	14.48B
ZYDUS LIFESCIENCES LIMITED	+57.58%	12.72B
THE MEDICINES COMPANY	-0.05%	6.79B
ONO PHARMACEUTICAL CO., LTD.	-10.69%	6.71B
STADA ARZNEIMITTEL	-8.87%	5.73B
ASPEN PHARMACARE HOLDINGS LIMITED	+14.68%	5.5B